Apart from controlling the cytokine storm to maintain immune homeostasis, immune checkpoint inhibitors (ICIs) have the potential to reverse CD8+ T cell exhaustion, which is a feature of persistent infectious diseases like COVID-19 [159,160]. The gene discussed is CD8A; the disease is COVID-19.